As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement. We are privileged to support researchers spanning the full spectrum of biomedical science, and we invite you to explore many of these impactful studies on our Literature Page. Reflecting the creativity and rigor of our global user community, in 2025 there were over 200 publications citing HALO® in peer-reviewed high-impact journals, with an average impact factor around 21.

Our 14th year was filled with milestones, with each one being the product of the dedication and expertise of numerous members across our global team. We were fortunate to welcome several new colleagues in 2025, with each addition bringing fresh perspectives, unique skills, and a shared dedication to our mission of powering the future of pathology. Our team spent the year crafting new digital pathology tools for ground-breaking research, securing expanded regulatory clearance for our clinical products, and developing AI algorithms for diagnostics and the future of precision medicine. If you’d like to learn more about the team and culture that fuel our work, we invite you to listen to the recent People of Pathology Podcast episode featuring Adam Smith, our Chief Commercial Officer. 

PARTNERSHIP NEWS

In 2025, Indica Labs strengthened and expanded its global collaborations, forging partnerships designed to advance digital pathology innovation in both clinical and life science applications. One of the year’s most exciting milestones was the announcement of our strategic partnership with Leica Biosystems. Combining our AI and biomarker analysis expertise with Leica Biosystems’ portfolio of healthcare solutions and commercialization experience, this partnership uniquely positions us to deliver AI-powered companion diagnostics, powering the next generation of precision medicine. Steven Hashagen, our CEO, noted, “we are delighted to team up with Leica Biosystems under this exciting arrangement… This collaboration between two companies dedicated to open pathology offers the potential to break down some of the barriers that prevent patients from receiving fast, reliable diagnoses and effective therapies.”   

Our partnership with Leica Biosystems is already delivering exciting new resources for the pathology community, including the FDA 510(k) clearance of our HALO AP Dx enterprise pathology platform for primary diagnosis in conjunction with the Leica Biosystems Aperio GT 450 DX Scanner. This clearance marks a significant step forward in interoperability and functionality, providing pathologists with a comprehensive platform for diagnostic workflows in digital pathology paired with the industry leading scanner for diagnostics that supports both SVS and DICOM image files.  

Another accomplishment of our partnership was Leica Biosystems’ launch of Aperio HALO AP and the Aperio AI Store. Aperio HALO AP is an advanced AI-powered image management solution developed in conjunction with Indica Labs and is the gateway to the Aperio AI Store, a scalable analysis platform incorporating powerful analysis applications, including select HALO Clinical AI tools. 

LIFE SCIENCE PRODUCT UPDATES

2025 was an outstanding year for product innovation at Indica Labs, marked by major platform updates, new AI capabilities, and continued expansion of our clinical and research toolsets. The year saw two major releases for HALO, HALO AI, and HALO Link, with versions 4.1 and 4.2 offering enhanced performance, expanded options for AI model training and integration, additional annotation tools, new features for highplex fluorescence workflows, and much more. You can learn more about these releases in the blog posts announcing version 4.1 and version 4.2.  

In 2025 we were also thrilled to unveil the HALO High Dimensional Analysis module, a powerful tool that enables exploratory analysis of cells or objects across whole slide images using dimensionality reduction and unsupervised clustering. Without ever leaving HALO, users can now leverage the UMAP dimensionality reduction technique and K-means and PhenoGraph clustering algorithms with a live link between results and the original image(s).  

Our existing HALO modules also saw exciting updates, with Muscle Fiber BF and Muscle Fiber FL modules gaining support for AI-powered nuclear and membrane segmentation and interactive markup images. Interactive markup functionality was also expanded to the HALO Vacuole, Object Colocalization BF, and Object Colocalization FL modules. 

CLINICAL PRODUCT UPDATES 

Our development team was also busy on the clinical side, delivering major advancements with the latest release of our CE-IVDR marked, AI-powered enterprise digital pathology platform HALO AP®. Version 2.4 introduced features supporting case conferencing, external consultants, enterprise workflow and data storage needs, interactive markup viewing, and much more.  

Our portfolio of HALO Clinical AI tools also expanded in 2025. We introduced CRC Macrodissect AI, a new addition to our macrodissection suite designed to assist in colorectal cancer tumor content scoring and selecting regions of interest for improved downstream molecular testing. We also expanded the capabilities of our Breast IHC AI tool, which now supports automated detection of low and ultralow HER2 expression, addressing the growing need for more precise stratification in breast cancer care. You can learn more about the capabilities of these powerful AI tools and how they integrate seamlessly into HALO AP® in this sneak peek webinar, and sign up for our Learning Portal to view tutorial videos, user guides, and release notes for all of our products. 

CLINICAL DEPLOYMENTS  

From 2024-2025 our clinical revenue increased 200% year-over-year, as many major medical institutions, top globally ranked pharmaceutical companies, and multiple comprehensive cancer centers confidently adopted HALO AP® for their clinical workflows. This magnitude of implementation reflects the robust capabilities of our clinical solutions as well as the rigorous demands set forth by the FDA. The expanded FDA 510(k) clearance of HALO AP Dx was the next major step in a plan that includes regulatory pathways across multiple clinical products in 2026. We look forward to sharing more news in 2026, and invite you to read our announcements with Versant Diagnostics and several members of the South West London Pathology network to learn about some of the HALO AP® deployments in 2025. 

EVENTS

In 2025, Indica Labs once again had an active presence at scientific meetings across the globe, showcasing our software and services to diverse research and clinical communities. Our user group meetings in Boston, Vienna, the San Francisco Bay Area, Tokyo, and London drew hundreds of attendees to hear our guest speakers share innovative HALO applications spanning academia, industry, and healthcare. 

Beyond our own meetings, the Indica team participated in more than 20 conferences throughout North America, Europe, and Asia. These events provided valuable opportunities to see many long-time partners, make new connections, and present posters and talks featuring the latest capabilities across our HALO platforms. 

We also continued to expand our resources for customer education, hosting more than a dozen webinars over the course of the year. These sessions included expert-led masterclasses, product demonstrations, and HALO user presentations illustrating how HALO, HALO AI, and HALO Link are being used to advance research in chronic traumatic encephalopathy and autoimmune diseases. If you missed any of these events, visit the webinars section on our News and Events page to watch the recordings. 

CUSTOMER SUPPORT

In 2025, we released many new resources for both the basic research and clinical communities, including application notes on high dimensional and spatial analysis, a white paper exploring HALO AP® integrations, and a case study on Mid-Atlantic Permanente Medical Group’s deployment of Breast IHC AI in HALO AP®. We also added numerous posts to our blog in 2025, with topics including antibody-drug conjugate research using HALO, the impact of digital pathology on clinical trials, our support for open pathology, and high dimensional analysis in HALO. Check out our Resource Center to browse our collection of blog posts, app notes, webinars, and other materials, and subscribe to our newsletter using the form at the bottom of our homepage to stay up to date on the latest Indica Labs news and resources. 

DIGITAL PATHOLOGY SERVICES 

2025 was a busy year for new and expanded offerings from our service teams, with our Indica Labs Pharma Services offering quantitative image analysis studies designed and performed to Good Clinical Practice (GCP) standards. “Since 2017, customers from pharma, biotech, and CROs have trusted us to help them solve complex image analysis challenges and meet critical deadlines,” noted Doug Bowman, VP of Pharma Services. “Our GCP image analysis service builds on this foundation, enabling us to serve our customers across more studies and at the highest standards of clinical research.” 

For our teams supporting integration and migration services and AI-powered companion diagnostics development, our partnership with Leica Biosystems meant a year full of activity. 2025 saw increasing numbers of customers looking to migrate from legacy image management systems to our HALO AP® and HALO Link enterprise pathology platforms, keeping our integration and migration services team busy. Meanwhile, announcement of the end-to-end companion diagnostics development capability provided by our partnership with Leica Biosystems kept teams across Indica Labs busy supporting pharma companies looking to leverage our expertise. 

LOOKING FORWARD TO 2026

At Indica Labs, we are energized by the momentum built in 2025 and anticipate an even more exciting year for our customers in 2026. Our development teams are hard at work on the next wave of advances across our platforms, and we look forward to sharing these innovations in the coming year. From further refining the user experience to offering new AI tools and securing additional regulatory clearances, we remain committed to empowering our customers with the solutions they need to advance their research and clinical discoveries. 

We extend our deepest gratitude to everyone who partnered with us, attended our events, or otherwise contributed to the HALO community throughout 2025, and we look forward to supporting your digital pathology goals and achieving even more together in 2026!  

HALO AP Dx (K252762) is FDA-cleared for primary diagnostic use with the Leica Biosystems’ Aperio GT 450 DX Scanner and Hamamatsu NanoZoomer® S360MD Slide scanner in the USA. In addition, HALO AP Dx provides built-in compliance with FDA 21 CFR Part 11 and HIPAA. 

Breast IHC AI is For Research Use Only and not intended for clinical diagnostic use. Breast IHC AI is accessed via the HALO AP® enterprise digital pathology platform. 

CRC Macrodissect AI is not a medical device in the EU/UK and is not intended to be used for diagnostic purposes. CRC Macrodissect AI is accessed via the HALO AP® enterprise digital pathology platform. CRC Macrodissect AI is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use.   

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. 

WBS-MAR-000016v1